Filtered By:
Condition: Atrial Fibrillation
Drug: Aspirin

This page shows you your search results in order of relevance. This is page number 11.

Order by Relevance | Date

Total 563 results found since Jan 2013.

Recurrent Stroke With Rivaroxaban Compared With Aspirin
This secondary analysis of a randomized clinical trial investigates whether rivaroxaban is associated with a reduction in recurrent stroke among patients with embolic stroke of undetermined source who have an increased risk of atrial fibrillation.
Source: JAMA Neurology - April 8, 2019 Category: Neurology Source Type: research

Recurrent Stroke With Rivaroxaban Compared With Aspirin According to Predictors of Atrial Fibrillation
This secondary analysis of a randomized clinical trial investigates whether rivaroxaban is associated with a reduction in recurrent stroke among patients with embolic stroke of undetermined source who have an increased risk of atrial fibrillation.
Source: JAMA Neurology - July 1, 2019 Category: Neurology Source Type: research

Aspirin Therapy and Risk of Subdural Hematoma: Meta-analysis of Randomized Clinical Trials
Conclusions: Based on the limited available data, it is uncertain whether aspirin therapy increases the risk of subdural hematoma: the observed 1.6-fold increased risk was not statistically significant. The incidence of subdural hematoma during aspirin therapy is low but varies widely depending upon the age of the patient population.
Source: Journal of Stroke and Cerebrovascular Diseases - February 18, 2013 Category: Neurology Authors: Ben J. Connolly, Lesly A. Pearce, Tobias Kurth, Carlos S. Kase, Robert G. Hart Tags: Original Articles Source Type: research

Effect of Apixaban on All-Cause Mortality in Atrial Fibrillation: An Imputed Placebo Analysis (I2-1.001)
CONCLUSIONS: This imputed placebo analysis suggests that apixaban significantly reduces all-cause mortality by about one-third in patients with AF.Study Supported by: Bristol-Myers Squibb Company and Pfizer Inc. Editorial assistance in formatting the abstract to ensure compliance with AAN guidelines was provided by Stephanie Finucane of Caudex Medical and was funded by Bristol-Myers Squibb Company and Pfizer Inc.Disclosure: Dr. McMurray has nothing to disclose. Dr. Hart has received personal compensation for activities with Sanofi-Aventis Pharmaceuticals Inc., and Bristol-Myers Squibb Co. Dr. Flaker has received personal c...
Source: Neurology - April 9, 2014 Category: Neurology Authors: McMurray, J., Hart, R., Flaker, G., Lopes, R., Wang, J., Hanna, M., Alexander, J., Granger, C., Wallentin, L. Tags: New Antithrombotic Agents for Stroke Prevention Poster Presentations Source Type: research

Stroke/thromboembolism and intracranial hemorrhage in a 'real world' atrial fibrillation population: The CAFBO STUDY (Complications of Atrial Fibrillation in the BOlogna area).
CONCLUSION IEs occurred mainly in elderly patients who received ASA or no treatment. Half of anticoagulated patients with IEs had subtherapeutic INRs. Therapeutic approaches to elderly subjects with AF require an effective anticoagulant treatment strategy. PMID: 24810397 [PubMed - as supplied by publisher]
Source: Chest - May 8, 2014 Category: Respiratory Medicine Authors: Palareti G, Salomone L, Cavazza M, Guidi M, Muscari A, Boriani G, Di Micoli A, Guizzardi G, Procaccianti G, Guidetti A, Binetti N, Malservisi S, Masina M, Viola A, Bua V, Ongari M, Diaspri G, Lip GY Tags: Chest Source Type: research

NICE advises against aspirin for cutting stroke risk in AF patients
The National Institute for Health and Care Excellence has recommended that people with atrial fibrillation are prescribed an anticoagulant instead of aspirin to reduce their risk of stroke.
Source: Nursing Times Breaking News - June 20, 2014 Category: Nursing Source Type: news

Common flaws exist in published cost-effectiveness models of pharmacologic stroke prevention in atrial fibrillation
Conclusion: Pharmacologic SPAF cost-effectiveness models have been extensively reported, but many may have flaws giving reason for decision makers to use caution. We provide 10 recommendations to avoid common flaws in SPAF cost-effectiveness models.
Source: Journal of Clinical Epidemiology - July 14, 2014 Category: Epidemiology Authors: Brendan L. Limone, William L. Baker, Elizabeth S. Mearns, C. Michael White, Jeffrey Kluger, Craig I. Coleman Tags: Review Articles Source Type: research

Cost-effectiveness of rivaroxaban for stroke prevention in atrial fibrillation in the Portuguese setting
Conclusion The results showed that rivaroxaban may be a cost-effective alternative compared with warfarin or real-world prescribing in Portugal.
Source: Revista Portuguesa de Cardiologia - November 6, 2014 Category: Cardiology Source Type: research

Aspirin too risky for stroke patients, NICE says
Adults with atrial fibrillation (AF) should no longer be prescribed aspirin to prevent stroke, NICE guidance released today said Hide related content:  Show related content read more
Source: Management in Practice - July 10, 2015 Category: Practice Management Authors: ltrevallion Tags: *** Editor ' s Pick Latest News Source Type: news

Experts Say Abandon Aspirin for Stroke Prevention in AFib
SNOWMASS, CO — It’s time to eliminate the practice of prescribing aspirin for stroke prevention in patients with atrial fibrillation and a CHA2DS2-VASc score of 1, two eminent cardiologists agreed at the Annual Cardiovascular Conference at Snowmass.
Source: Caring for the Ages - February 26, 2016 Category: Health Management Authors: Bruce Jancin Source Type: news

Many atrial fibrillation patients at risk of stroke treated with aspirin over anticoagulants
Around 40% of atrial fibrillation patients who have an intermediate or high risk of stroke are treated only with aspirin, even though aspirin is less effective than oral anticoagulation, according to new research.
Source: The Pharmaceutical Journal - June 24, 2016 Category: Drugs & Pharmacology Source Type: research

Anticoagulation Treatment for Stroke Prevention in Atrial Fibrillation Is Increasing, But Further Improvements Needed
A recent paper by Hsu et  al.(1) assessed antithrombotic treatment among atrial fibrillation (AF) patients. The data, from the American College of Cardiology PINNACLE (Practice Innovation and Clinical Excellence) registry between 2008 and 2012, showed that 61.8% of patients with moderate-to-high stroke risk received anticoagulant therapy with either warfarin or newer direct oral anticoagulants (DOACs). The investigators and an editorial commentary noted the alarming prevalence of aspirin-only treatment despite clear evidence that anticoagulants are superior for prevention of thromboembolism in AF (1,2).
Source: Journal of the American College of Cardiology - November 29, 2016 Category: Cardiology Source Type: research

Long ‐term aspirin does not lower risk of stroke and increases bleeding risk in low‐risk atrial fibrillation ablation patients
ConclusionsAfter catheter ablation, low risk patients do not benefit from long‐term aspirin therapy, but are at risk for higher rates of bleeding when compared to no therapy or warfarin.
Source: Journal of Cardiovascular Electrophysiology - September 26, 2017 Category: Cardiology Authors: Victoria Jacobs, Heidi T. May, Tami L. Bair, Brian G. Crandall, Michael J. Cutler DO, John D. Day, Charles Mallender, Jeffrey S. Osborn, J. Peter Weiss, T. Jared Bunch Tags: ORIGINAL ARTICLE Source Type: research

Risk of Stroke vs. Intracerebral Hemorrhage in Patients with Non-Valvular Atrial Fibrillation Undergoing Percutaneous Coronary Intervention: A Systematic Review and Meta-Analysis of Randomized Controlled Trials Comparing Dual vs. Triple Antithrombotic Therapy
About 15% of patients with non-valvular atrial fibrillation might require percutaneous coronary interventions (PCIs) with stent placement to treat obstructive coronary artery disease. Dual antiplatelet therapy (DAPT) with acetylsalicylic acid (aspirin) and P2Y12 antagonist is recommended after PCI. Patients requiring DAPT also require treatment with oral anticoagulation for atrial fibrillation. We conducted a meta-analysis to identify the antithrombotic regimen associated with the lowest rate of bleeding and thromboembolic events in non-valvular atrial fibrillation after PCI.
Source: Journal of Stroke and Cerebrovascular Diseases - February 9, 2021 Category: Neurology Authors: Aaron Desai, Cesar Escamilla-Ocanas, Deepika Dilip, Hamidreza Saber, Rahul Damani Source Type: research

Stenosis Length and Degree Interact With the Risk of Cerebrovascular Events Related to Internal Carotid Artery Stenosis
Conclusion: We found a statistically insignificant tendency for the ultrasound-measured length of sICAS<70% to be longer than that of sICAS≥70%. Moreover, the ultrasound-measured length of sICAS<90% was significantly longer than that of sICAS 90%. Among patients with sICAS≥70%, the degree and length of stenosis were inversely correlated. Larger studies are needed before a clinical implication can be drawn from these results. Introduction Internal carotid artery stenosis (ICAS) causes around one-fifth of ischemic cerebrovascular stroke and has the highest risk of early stroke recurrence...
Source: Frontiers in Neurology - April 8, 2019 Category: Neurology Source Type: research